Form 8-K - Current report:
SEC Accession No. 0001193125-24-273688
Filing Date
2024-12-10
Accepted
2024-12-09 21:03:01
Documents
15
Period of Report
2024-12-09
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d873794d8k.htm   iXBRL 8-K 25983
2 EX-99.1 d873794dex991.htm EX-99.1 16340
6 GRAPHIC g873794g1209161551105.jpg GRAPHIC 2206
  Complete submission text file 0001193125-24-273688.txt   169851

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA lyel-20241209.xsd EX-101.SCH 2845
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE lyel-20241209_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lyel-20241209_pre.xml EX-101.PRE 10809
17 EXTRACTED XBRL INSTANCE DOCUMENT d873794d8k_htm.xml XML 3508
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

EIN.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40502 | Film No.: 241536881
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)